<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01054170</url>
  </required_header>
  <id_info>
    <org_study_id>D0520C00014</org_study_id>
    <nct_id>NCT01054170</nct_id>
  </id_info>
  <brief_title>Effect on Structural Changes in Airways, Measured by MSCT, of Twice Daily 60mg AZD9668 for 12 Weeks in Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <official_title>A 12-week, Phase II, Double-blind, Placebo-Controlled, Randomised, Parallel-Group, Multi-Centre Study to Assess the Effect of 60mg AZD9668 Administered Orally Twice Daily on Structural Changes in the Airways by Multi-Slice Computed Tomography in Patients With Chronic Obstructive Pulmonary Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to evaluate structural changes effected by AD9668 in
      the airways of adults with Chronic Obstructive Pulmonary Disease (COPD) by Multi-Slice
      Computed Tomography (MSCT)
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AWT-Pi10 (Airway Wall Thickness of a Theoretical Airway With an Internal Perimeter of 10 mm)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>AWT-Pi10 (mm) as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>5th Generation Wall Area Percentage</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>5th Generation Wall Area Percentage as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Air Trapping Index (ATI) on Expiratory Scans</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>ATI Percentage as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Inspiratory Capacity (IC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Inspiratory Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Total Lung Capacity (TLC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Total Lung Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Functional Residual Capacity (FRC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Functional Residual Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Residual Volume (RV)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Residual volume (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Specific Airway Conductance (SGaw)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Specific Airway Conductance as a measure of lung function. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Diffusion Capacity of Carbon Monoxide (DLco)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Capacity of Carbon Monoxide as a measure of lung function. End of treatment Least Squares Mean.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Forced Vital Capacity (FVC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Forced Vital Capacity (FVC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-bronchodilator Slow Vital Capacity (SVC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Slow Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-bronchodilator Slow Vital Capacity (SVC)</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>Slow Vital capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Morning (Daily Recordings)</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Expiratory Flow (PEF) Evening (Daily Recordings)</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each evening .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Morning (Daily Recordings)</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Forced Expiratory Volume in 1 Second (FEV1) Evening (Daily Recordings)</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each evening.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Breathlessness, Cough and Sputum Scale (BCSS) Total Score</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Overall Score</measure>
    <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
    <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Reliever Free Days in Last Six Weeks of Treatment</measure>
    <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
    <description>Percentage of reliever free days in last 6 weeks on treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>Exacerbations were recorded at all study visits (after 1, 4, 8, and 12 weeks of treatment and at follow up)</time_frame>
    <description>Number of patients experiencing disease exacerbations on treatment.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">52</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>AZD9668</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD9668</intervention_name>
    <description>2 x 30 mg oral tablets twice daily (bid) for 12 weeks</description>
    <arm_group_label>AZD9668</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>2 x matched placebo to oral tablet twice daily (bid) for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of COPD with symptoms over 1 year

          -  FEV1/FVC &lt; 70% and FEV1 &gt;= 40 and &lt; =70 % of predicted post-bronchodilator

          -  Ex-smokers for at least 12 months

        Exclusion Criteria:

          -  Past history or current evidence of clinically significant heart disease

          -  Current diagnosis of asthma

          -  Worsening of COPD requiring hospitalisation and/or treatment with antibiotics and/or
             an increase in inhaled steroid dose and/or oral steroids within 4 weeks of study visit
             1b
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Professor Asger Dirksen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gentofte Hospital, Department of Lung Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hellerup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hvidovre</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Odensec</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bucuresti</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kyiv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Denmark</country>
    <country>Netherlands</country>
    <country>Romania</country>
    <country>Ukraine</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>January 24, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">July 25, 2012</results_first_posted>
  <last_update_submitted>August 14, 2012</last_update_submitted>
  <last_update_submitted_qc>August 14, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 20, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Chronic</keyword>
  <keyword>obstructive</keyword>
  <keyword>pulmonary</keyword>
  <keyword>lung</keyword>
  <keyword>respiratory disease</keyword>
  <keyword>efficacy</keyword>
  <keyword>placebo-controlled</keyword>
  <keyword>COPD</keyword>
  <keyword>FEV1</keyword>
  <keyword>St Georges Respiratory Questionnaire</keyword>
  <keyword>Computed Tomography</keyword>
  <keyword>MSCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enrolled: 06 January 2010; Last patient completed: 17 November 2010; Twelve centres across 5 countries participated in this study: Canada (2), Denmark (3), The Netherlands (2), Romania (2) and Ukraine (3).</recruitment_details>
      <pre_assignment_details>Tiotropium maintenance therapy and reliever medication were commenced at screening, except for patients on inhaled corticosteroids (ICS, ICS/LABA) who were required to stop these at enrolment and commence on tiotropium and reliever medication at the same time. These patients received tiotropium for a period of at least 3 weeks before screening.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>AZD9668</title>
          <description>AZD9668 2x30mg bid</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo 2 tablets bid</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
                <participants group_id="P2" count="27"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD9668</title>
          <description>AZD9668 2x30mg bid</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo 2 tablets bid</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
            <count group_id="B2" value="27"/>
            <count group_id="B3" value="52"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.2" spread="65"/>
                    <measurement group_id="B2" value="7.7" spread="66"/>
                    <measurement group_id="B3" value="7.45" spread="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>AWT-Pi10 (Airway Wall Thickness of a Theoretical Airway With an Internal Perimeter of 10 mm)</title>
        <description>AWT-Pi10 (mm) as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>AWT-Pi10 (Airway Wall Thickness of a Theoretical Airway With an Internal Perimeter of 10 mm)</title>
          <description>AWT-Pi10 (mm) as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>mm</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.84" spread="0.021" lower_limit="0.021"/>
                    <measurement group_id="O2" value="3.83" spread="0.017" lower_limit="0.017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>5th Generation Wall Area Percentage</title>
        <description>5th Generation Wall Area Percentage as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>5th Generation Wall Area Percentage</title>
          <description>5th Generation Wall Area Percentage as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Percentage Area</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="19"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.21" spread="0.275" lower_limit="0.275"/>
                    <measurement group_id="O2" value="65.94" spread="0.234" lower_limit="0.234"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Air Trapping Index (ATI) on Expiratory Scans</title>
        <description>ATI Percentage as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Air Trapping Index (ATI) on Expiratory Scans</title>
          <description>ATI Percentage as a measure of structural changes in airways. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>ATI Percentage</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54.56" spread="1.706" lower_limit="1.706"/>
                    <measurement group_id="O2" value="57.12" spread="1.599" lower_limit="1.599"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Inspiratory Capacity (IC)</title>
        <description>Inspiratory Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Inspiratory Capacity (IC)</title>
          <description>Inspiratory Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.56" spread="0.154" lower_limit="0.154"/>
                    <measurement group_id="O2" value="2.39" spread="0.153" lower_limit="0.153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Total Lung Capacity (TLC)</title>
        <description>Total Lung Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Total Lung Capacity (TLC)</title>
          <description>Total Lung Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.03" spread="0.178" lower_limit="0.178"/>
                    <measurement group_id="O2" value="6.92" spread="0.177" lower_limit="0.177"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Functional Residual Capacity (FRC)</title>
        <description>Functional Residual Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Functional Residual Capacity (FRC)</title>
          <description>Functional Residual Capacity (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.41" spread="0.165" lower_limit="0.165"/>
                    <measurement group_id="O2" value="4.21" spread="0.158" lower_limit="0.158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Residual Volume (RV)</title>
        <description>Residual volume (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Residual Volume (RV)</title>
          <description>Residual volume (L) as a measure of lung function. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.64" spread="0.161" lower_limit="0.161"/>
                    <measurement group_id="O2" value="3.73" spread="0.161" lower_limit="0.161"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Specific Airway Conductance (SGaw)</title>
        <description>Specific Airway Conductance as a measure of lung function. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Specific Airway Conductance (SGaw)</title>
          <description>Specific Airway Conductance as a measure of lung function. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>1/[s*kPa]</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.52" spread="0.034" lower_limit="0.034"/>
                    <measurement group_id="O2" value="0.48" spread="0.034" lower_limit="0.034"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Diffusion Capacity of Carbon Monoxide (DLco)</title>
        <description>Capacity of Carbon Monoxide as a measure of lung function. End of treatment Least Squares Mean.</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Diffusion Capacity of Carbon Monoxide (DLco)</title>
          <description>Capacity of Carbon Monoxide as a measure of lung function. End of treatment Least Squares Mean.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>mmol/kPa*min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.49" spread="0.204" lower_limit="0.204"/>
                    <measurement group_id="O2" value="5.67" spread="0.209" lower_limit="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.048" lower_limit="0.048"/>
                    <measurement group_id="O2" value="1.49" spread="0.050" lower_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Expiratory Volume in 1 Second (FEV1)</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.60" spread="0.050" lower_limit="0.050"/>
                    <measurement group_id="O2" value="1.58" spread="0.050" lower_limit="0.050"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Forced Vital Capacity (FVC)</title>
        <description>Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Forced Vital Capacity (FVC)</title>
          <description>Forced Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.25" spread="0.084" lower_limit="0.084"/>
                    <measurement group_id="O2" value="3.14" spread="0.083" lower_limit="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Forced Vital Capacity (FVC)</title>
        <description>Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Forced Vital Capacity (FVC)</title>
          <description>Forced Vital Capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.34" spread="0.083" lower_limit="0.083"/>
                    <measurement group_id="O2" value="3.34" spread="0.080" lower_limit="0.080"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-bronchodilator Slow Vital Capacity (SVC)</title>
        <description>Slow Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-bronchodilator Slow Vital Capacity (SVC)</title>
          <description>Slow Vital Capacity (L) as a measure of lung function, measured before bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.42" spread="0.069" lower_limit="0.069"/>
                    <measurement group_id="O2" value="3.38" spread="0.068" lower_limit="0.068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-bronchodilator Slow Vital Capacity (SVC)</title>
        <description>Slow Vital capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Post-bronchodilator Slow Vital Capacity (SVC)</title>
          <description>Slow Vital capacity (L) as a measure of lung function, measured after bronchodilator (salbutamol) use in the clinic. End of treatment value or Last Observation Carried Forward (LOCF).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.56" spread="0.063" lower_limit="0.063"/>
                    <measurement group_id="O2" value="3.44" spread="0.061" lower_limit="0.061"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Morning (Daily Recordings)</title>
        <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Morning (Daily Recordings)</title>
          <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each morning.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="255.82" spread="9.956" lower_limit="9.956"/>
                    <measurement group_id="O2" value="244.16" spread="9.871" lower_limit="9.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Expiratory Flow (PEF) Evening (Daily Recordings)</title>
        <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each evening .</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Expiratory Flow (PEF) Evening (Daily Recordings)</title>
          <description>Peak Expiratory Flow (L/min) as a measure of lung function, measured at home by the patient each evening .</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="264.15" spread="10.02" lower_limit="10.02"/>
                    <measurement group_id="O2" value="254.31" spread="9.966" lower_limit="9.966"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Morning (Daily Recordings)</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Morning (Daily Recordings)</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each morning.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="0.065" lower_limit="0.065"/>
                    <measurement group_id="O2" value="1.29" spread="0.066" lower_limit="0.066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Forced Expiratory Volume in 1 Second (FEV1) Evening (Daily Recordings)</title>
        <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each evening.</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Forced Expiratory Volume in 1 Second (FEV1) Evening (Daily Recordings)</title>
          <description>Forced Expiratory Volume in 1 second (L) as a measure of lung function, measured at home by the patient each evening.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>L</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.51" spread="0.062" lower_limit="0.062"/>
                    <measurement group_id="O2" value="1.30" spread="0.064" lower_limit="0.064"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Breathlessness, Cough and Sputum Scale (BCSS) Total Score</title>
        <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale).</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Breathlessness, Cough and Sputum Scale (BCSS) Total Score</title>
          <description>Breathlessness, Cough and Sputum Scale, patient reported questionnaire as a measure of respiratory symptoms (reported on a 0 (best health status) to 12 (worst possible status) scale).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Total Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.33" spread="0.319" lower_limit="0.319"/>
                    <measurement group_id="O2" value="3.36" spread="0.301" lower_limit="0.301"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score</title>
        <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale).</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>EXAcerbations of Chronic Pulmonary Disease Tool (EXACT) Total Score</title>
          <description>EXAcerbations of Chronic pulmonary disease Tool, patient questionnaire as a measure of respiratory symptoms (reported as units on a 0 (best health status) to 100 (worst possible status) scale).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Total Score</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.48" spread="2.065" lower_limit="2.065"/>
                    <measurement group_id="O2" value="33.26" spread="2.013" lower_limit="2.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Overall Score</title>
        <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).</description>
        <time_frame>Measured after 12 weeks treatment (day 84)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>St George's Respiratory Questionnaire for COPD Patients (SGRQ-C) Overall Score</title>
          <description>St George's Respiratory Questionnaire for Chronic Obstructive Pulmonary Disease, as a measure of Quality of Life (reported on a % scale from 0 (best health status) to 100(worst possible status)).</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.64" spread="2.364" lower_limit="2.364"/>
                    <measurement group_id="O2" value="39.61" spread="2.389" lower_limit="2.389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Reliever Free Days in Last Six Weeks of Treatment</title>
        <description>Percentage of reliever free days in last 6 weeks on treatment.</description>
        <time_frame>Average from measurements recorded daily by patient in last 6 weeks of treatment.</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Reliever Free Days in Last Six Weeks of Treatment</title>
          <description>Percentage of reliever free days in last 6 weeks on treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>percentage of days</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.23" spread="6.394" lower_limit="6.394"/>
                    <measurement group_id="O2" value="26.43" spread="6.001" lower_limit="6.001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Exacerbations</title>
        <description>Number of patients experiencing disease exacerbations on treatment.</description>
        <time_frame>Exacerbations were recorded at all study visits (after 1, 4, 8, and 12 weeks of treatment and at follow up)</time_frame>
        <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
        <group_list>
          <group group_id="O1">
            <title>AZD9668</title>
            <description>AZD9668 2x30mg bid</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo 2 tablets bid</description>
          </group>
        </group_list>
        <measure>
          <title>Exacerbations</title>
          <description>Number of patients experiencing disease exacerbations on treatment.</description>
          <population>The efficacy analysis set for each outcome measure includes those patients who received at least one dose of investigational product and for whom a baseline and at least one post-randomisation measurement is available for that outcome measure. Patients were analysed by to randomised treatment in accordance with the intention to treat principle.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
                <count group_id="O2" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>AZD9668</title>
          <description>AZD9668 2x30mg bid</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo 2 tablets bid</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>POST PROCEDURAL COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (13.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DRY MOUTH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 13.1">ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA 13.1">DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>BRONCHIAL WALL THICKENING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>aztrial_results_posting@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

